ETNB - NASDAQ

89bio, Inc.

ETNB·NASDAQ

$14.84

+0.0000%

HealthcareBiotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.20B

EPS-3.5100

P/E Ratio-2.23

Earnings Date11/06/2025

478.69M

Assets

-20%

3Y+195.0%

5Y+401.0%

10Y+4110.0%

77.90M

Total Liabilities

30%

3Y+114.0%

5Y+1289.0%

10Y+184.0%

400.79M

Total Equity

-25%

3Y+218.0%

5Y+346.0%

10Y-2596.0%

89bio, Inc. Funding & Solvency Profile

ETNB · NASDAQ

Current Assets

Cash & Cash Equivalents126.06M

Net Receivables0.00

Inventory0.00

Other Current Assets0.00

Total Current Assets476 M

Non-Current Assets

Property, Plant & Equipment1.59M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets640.00K

Total Non-Current Assets2 M

Total Assets

478.69M

Financial Health Analysis

Current Ratio

13.19x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.19x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

440 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

89bio, Inc. Balance Sheet

ETNB • NASDAQ

89bio, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	126.1M	316.2M	55.3M	52.4M	98.2M	93.4M	11.2M
Short-Term Investments	313.9M	262.7M	132.9M	98.3M	106.4M	0.0	0.0
Cash & Short-Term Investments	440M	578.9M	188.2M	150.7M	204.7M	93.4M	11.2M
Prepaids	36.5M	14.7M	7.9M	11.2M	5.5M	2M	59K
Other Current Assets	0.0	0.0	0.0	0.0	0.0	0.0	23K
Total Current Assets	476.5M	593.5M	196.1M	162M	210.2M	95.3M	11.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	1.6M	2.3M	455K	150K	166K	155K	33K
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	20K
Other Non-Current Assets	640K	396K	289K	290K	706K	72K	0.0
Total Non-Current Assets	2.2M	2.7M	744K	440K	872K	227K	53K
Total Assets	478.7M	596.3M	196.8M	162.4M	211.1M	95.6M	11.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	15.4M	8.6M	12.5M	6.8M	2.1M	989K	1.5M
Accounts Payable	15.4M	8.6M	12.5M	6.8M	2.1M	989K	1.5M
Accrued Expenses	13.1M	6.2M	4.2M	3.2M	2.6M	1.4M	890K
Short Term Debt	0.0	0.0	168K	2.5M	0.0	0.0	0.0
Capital Lease Obligations (Current)	727K	496K	168K	0.0	0.0	0.0	0.0
Other Current Liabilities	6.9M	14.3M	7.6M	7M	3.5M	3.2M	2M
Total Current Liabilities	36.1M	29.6M	24.6M	19.5M	8.1M	5.6M	4.4M
NON-CURRENT LIABILITIES
Long Term Debt	35.7M	24.8M	20.2M	16.9M	0.0	0.0	0.0
Other Non-Current Liabilities	4.9M	3.7M	0.0	30K	0.0	0.0	23.1M
Total Non-Current Liabilities	41.8M	30.4M	20.4M	16.9M	0.0	0.0	23.1M
Capital Lease Obligations	1.8M	2.3M	354K	0.0	0.0	0.0	0.0
Total Liabilities	77.9M	60M	45M	36.5M	8.1M	5.6M	27.4M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	-118K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	95.6M	24.7M
Common Stock	120K	93K	51K	20K	20K	14K	1K
Additional Paid-In Capital	1.2B	993.5M	467.4M	339.2M	326M	163.5M	118K
Retained Earnings	-824.5M	-457.4M	-315.2M	-213.2M	-123.1M	-73.6M	-16.2M
Accumulated Other Comprehensive Income/Loss	563K	190K	-350K	-64K	-10K	-95.6M	-6K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-24.6M
Total Stockholders' Equity	400.8M	536.3M	151.8M	126M	203M	89.9M	-16.1M
Total Equity	400.8M	536.3M	151.8M	126M	203M	89.9M	-16.1M
SUMMARY
Total Liabilities & Equity	478.7M	596.3M	196.8M	162.4M	211.1M	95.6M	11.4M
Total Investments	313.9M	262.7M	132.9M	98.3M	106.4M	0.0	0.0
Total Debt	37.5M	27.1M	20.5M	19.4M	0.0	0.0	0.0
Net Debt	-88.5M	-289.1M	-35.2M	-131.3M	-204.7M	-93.4M	-11.2M
Shares Outstanding	148,299,162	148,299,162	148,299,162	148,299,162	148,299,162	148,299,162	148,299,162

SEC Filings

ETNB - Filing history and reports

No SEC filings available for ETNB

Related Guides

Blog Categories

Continue your ETNB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.